DAVID ALAN KASS

Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease BALTIMORE, MD NPI 1588605877

General Payments — all program years on this page

$94,949.83

  • Category: General Payments
  • Program years: PY2018–2023
  • Record count: 85
  • As of (CMS publication): 2026-01-23

Latest program year (PY2023): $12,678.19 across 16 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2023) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $11,629.504
Travel and Lodging $765.527
Education $164.451
Food and Beverage $118.724

By paying entity

Latest program year (PY2023) · sorted by reported total.

Paying entityAmountRecords
Amgen Inc. $7,586.002
Acerta Pharma LLC $2,953.501
Merck Sharp & Dohme Corporation $1,090.001
Eli Lilly and Company $1,048.6912

By program year

Program yearAmountRecords
2018 $16,296.9620
2019 $32,691.8833
2020 $21,072.009
2021 $3,675.002
2022 $8,535.805
2023 $12,678.1916

Records — PY2023 (16)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1015770907 AstraZeneca Pharmaceuticals LP $2,953.50 01/12/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1020817317 Amgen Inc. $5,801.00 10/16/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1020817319 Amgen Inc. $1,785.00 10/16/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1031322725 Eli Lilly and Company $25.47 09/21/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1031322727 Eli Lilly and Company $78.00 09/20/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1031328507 Eli Lilly and Company $319.04 09/18/2023 Travel and Lodging Undisputed 01/23/2026 View at CMS
1031328509 Eli Lilly and Company $2.11 09/21/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1031328511 Eli Lilly and Company $23.12 09/21/2023 Travel and Lodging Undisputed 01/23/2026 View at CMS
1031335473 Eli Lilly and Company $67.41 09/21/2023 Travel and Lodging Undisputed 01/23/2026 View at CMS
1031335475 Eli Lilly and Company $136.00 09/21/2023 Travel and Lodging Undisputed 01/23/2026 View at CMS
1031335477 Eli Lilly and Company $12.95 09/21/2023 Travel and Lodging Undisputed 01/23/2026 View at CMS
1031348429 Eli Lilly and Company $164.45 09/21/2023 Education Undisputed 01/23/2026 View at CMS
1031363753 Eli Lilly and Company $22.00 12/18/2023 Travel and Lodging Undisputed 01/23/2026 View at CMS
1031369845 Eli Lilly and Company $13.14 09/21/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1031369849 Eli Lilly and Company $185.00 09/21/2023 Travel and Lodging Undisputed 01/23/2026 View at CMS
1048424445 Merck Sharp & Dohme LLC $1,090.00 06/26/2023 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.